All data are based on the daily closing price as of April 28, 2025
h
Hanmi Pharm. Co.
128940.KO
165.58 USD
-1.43
-0.86%
Overview
Last close
165.58 usd
Market cap
2.10B usd
52 week high
279.43 usd
52 week low
146.58 usd
Target price
244.91 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
2.0392
Price/Book Value
2.8051
Enterprise Value
2.32B usd
EV/Revenue
2.2379
EV/EBITDA
11.4239
Key financials
Revenue TTM
1.04B usd
Gross Profit TTM
566.06M usd
EBITDA TTM
214.67M usd
Earnings per Share
N/A usd
Dividend
0.87 usd
Total assets
1.37B usd
Net debt
200.43M usd
About
Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company's products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company has a research collaboration with MEDIC Life Sciences Inc. to identify cancer biomarkers. The company was founded in 1973 and is based in Hwaseong-si, South Korea.